Affordable Access

Publisher Website

Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma.

  • Myers, Regina M1
  • Hill, Brian T2
  • Shaw, Bronwen E3
  • Kim, Soyoung3, 4
  • Millard, Heather R3
  • Battiwalla, Minoo5
  • Majhail, Navneet S6
  • Buchbinder, David7
  • Lazarus, Hillard M8
  • Savani, Bipin N9
  • Flowers, Mary E D10
  • D'Souza, Anita3
  • Ehrhardt, Matthew J11
  • Langston, Amelia12
  • Yared, Jean A13
  • Hayashi, Robert J14
  • Daly, Andrew15
  • Olsson, Richard F16, 17
  • Inamoto, Yoshihiro18
  • Malone, Adriana K19
  • And 14 more
  • 1 Divisions of Hematology and Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, Pennsylvania.
  • 2 Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.
  • 3 Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • 4 Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • 5 Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland.
  • 6 Blood and Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.
  • 7 Division of Pediatric Hematology, Children's Hospital of Orange County, Orange, California.
  • 8 Seidman Cancer Center, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio.
  • 9 Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
  • 10 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • 11 St Jude Children's Research Hospital, Memphis, Tennessee.
  • 12 Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia. , (Georgia)
  • 13 Blood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Maryland.
  • 14 Division of Pediatric Hematology/Oncology, Department of Pediatrics, Washington University School of Medicine in St. Louis, St. Louis, Missouri.
  • 15 Tom Baker Cancer Center, Calgary, Alberta, Canada. , (Canada)
  • 16 Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden. , (Sweden)
  • 17 Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden. , (Sweden)
  • 18 Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan. , (Japan)
  • 19 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • 20 Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts.
  • 21 Department of Pediatric Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts.
  • 22 Department of Pediatrics, Uniformed Services Industry of the Health Sciences, Bethesda, Maryland.
  • 23 Division of Hematology, Ohio State University Medical Center, Columbus, Ohio.
  • 24 University of Miami, Miami, Florida.
  • 25 Department of Medical Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, Pennsylvania.
  • 26 Division of Hematology-Oncology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • 27 Adult Bone Marrow Transplant, University Hospitals Bristol NHS Trust, Bristol, United Kingdom. , (United Kingdom)
  • 28 Baylor University Medical Center, Dallas, Texas.
  • 29 Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
  • 30 Division of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, Washington.
  • 31 Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina.
  • 32 Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Department of Pediatrics, Columbia University Medical Center, New York, New York.
Published Article
Wiley (John Wiley & Sons)
Publication Date
Feb 15, 2018
DOI: 10.1002/cncr.31114
PMID: 29125192


Despite generally favorable outcomes, 2-year survivors of auto-HCT for cHL or DLBCL have an excess late-mortality risk in comparison with the general population and experience an assortment of late complications. Cancer 2018;124:816-25. © 2017 American Cancer Society.

Report this publication


Seen <100 times